Back
ESC Premium Access

Changes in glycated hemoglobin in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan

Session: Poster Session 1 - Treatment of the chronic heart failure
Topic: Pharmacotherapy
Event: ESC Congress 2019

Congress Presentation

9 more presentations in this session

Transcoronary transfer of Wharton's jelly mesenchymal pluripotent stem cells in patients with chronic ischaemic heart failure shows safety and unprecedented high-grade myocardial uptake

Speaker: Doctor A. Kozynacka (Krakow, PL)

Access
Abstract
Thumbnail

Effect of sacubitril-valsartan in reducing physical frailty in patients with advanced heart failure in waiting list for heart transplantation

Speaker: Doctor G. Benincasa (Naples, IT)

Access
Abstract
Slides
Thumbnail

Use of sacubitril-valsartan in an extensive long term follow up cohort in real life

Speaker: Doctor A. Garcia Quintana (Palmas de Gran Canaria, Las, ES)

Access
Abstract
Slides
Thumbnail

Valsartan reduces level of soluble ST2 and left ventricle remodeling in patients with dual chamber pacemaker

Speaker: Mrs E. Radzik (Zabrze, PL)

Access
Abstract
Thumbnail

Eligible patients for the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk

Speaker: Doctor X. Chen (Gothenburg, SE)

Access
Abstract
Slides
Thumbnail

Access the full session

Poster Session 1 - Treatment of the chronic heart failure

Speakers: Doctor A. Kozynacka, Doctor G. Benincasa, Doctor A. Garcia Quintana, Mrs E. Radzik, Doctor X. Chen
Access
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb